GSK Latest Headlines

GSK Stock Smashes 52-Week High On Strong Quarter, Dividend Hike

at www.benzinga.com (Wed, 4-Feb 8:12 AM)

GSK: Solid Near-Term Delivery, Enhanced Shareholder Returns, and Compelling 2031 Growth Upside Support Buy Rating

at www.tipranks.com (Wed, 4-Feb 7:57 AM)

Balancing Pipeline Upside and HIV Patent Cliff Risks: Justifying a Hold Rating Despite FX Drag and Valuation Richness

at www.tipranks.com (Wed, 4-Feb 6:57 AM)

Jefferies Remains a Buy on GlaxoSmithKline (GSK)

at www.tipranks.com (Wed, 4-Feb 6:16 AM)

Wave Life Sciences receives back rights to AATD therapy from GSK

at seekingalpha.com (Mon, 2-Feb 8:36 AM)

Earnings week ahead: AMZN, GOOG, PLTR, AMD, PFE, DIS, PYPL, ABBV, QCOM, SMCI, MRK, PEP, UBER, PM, and more

at seekingalpha.com (Sun, 1-Feb 8:07 AM)

The Week That Was, The Week Ahead: Macro and Markets, Feb. 1

at www.tipranks.com (Sun, 1-Feb 4:15 AM)

GSK Advances Shigella Vaccine Program With Completed Phase 2 Trial in African Infants

at www.tipranks.com (Fri, 30-Jan 11:30 AM)

GSK’s Long-Term Nucala Study in EGPA Nears the Finish Line: What Investors Should Know

at www.tipranks.com (Fri, 30-Jan 11:30 AM)

J&J wins EU backing for Akeega label expansion

at seekingalpha.com (Fri, 30-Jan 11:13 AM)

GlaxoSmithKline (GSK) Receives a Hold from Citi

at www.tipranks.com (Fri, 30-Jan 9:25 AM)

GSK Teams Up With Summit to Advance Novel Antibody Drug Combination in Solid Tumor Cancers

Market Chameleon (Mon, 12-Jan 7:11 AM)

FDA Greenlights GSK’s Exdensur, Offering Twice-Yearly Asthma Protection and 58% Reduction in Exacerbations

Market Chameleon (Wed, 17-Dec 7:56 AM)